BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23061466)

  • 21. Recent developments in computational prediction of HERG blockage.
    Wang S; Li Y; Xu L; Li D; Hou T
    Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human Ether-à-go-go Related Gene (hERG) Channel Blocking Aporphine Alkaloids from Lotus Leaves and Their Quantitative Analysis in Dietary Weight Loss Supplements.
    Grienke U; Mair CE; Saxena P; Baburin I; Scheel O; Ganzera M; Schuster D; Hering S; Rollinger JM
    J Agric Food Chem; 2015 Jun; 63(23):5634-9. PubMed ID: 26035250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels.
    Zhao J; Lian Y; Lu C; Jing L; Yuan H; Peng S
    J Ethnopharmacol; 2012 Jun; 141(2):685-91. PubMed ID: 21920426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HERG K+ channel blockade by the novel antiviral drug sophocarpine.
    Zhao XL; Qi ZP; Fang C; Chen MH; Lv YJ; Li BX; Yang BF
    Biol Pharm Bull; 2008 Apr; 31(4):627-32. PubMed ID: 18379053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico modelling--pharmacophores and hERG channel models.
    Recanatini M; Cavalli A; Masetti M
    Novartis Found Symp; 2005; 266():171-81; discussion 181-5. PubMed ID: 16050268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of berberine, liensinine and neferine on HERG channel expression].
    Wei T; Liang Z; Jin Y; Zhang L
    Zhongguo Zhong Yao Za Zhi; 2013 Jan; 38(2):239-44. PubMed ID: 23672049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revealing the structural basis of action of hERG potassium channel activators and blockers.
    Perry M; Sanguinetti M; Mitcheson J
    J Physiol; 2010 Sep; 588(Pt 17):3157-67. PubMed ID: 20643767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers.
    Thai KM; Ecker GF
    Mol Divers; 2009 Aug; 13(3):321-36. PubMed ID: 19219559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug block of the hERG potassium channel: insight from modeling.
    Stansfeld PJ; Gedeck P; Gosling M; Cox B; Mitcheson JS; Sutcliffe MJ
    Proteins; 2007 Aug; 68(2):568-80. PubMed ID: 17444521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
    Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
    Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues.
    ; Guo D; Klaasse E; de Vries H; Brussee J; Nalos L; Rook MB; Vos MA; van der Heyden MA; Ijzerman AP
    ChemMedChem; 2009 Oct; 4(10):1722-32. PubMed ID: 19725081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs.
    Durdagi S; Subbotina J; Lees-Miller J; Guo J; Duff HJ; Noskov SY
    Curr Med Chem; 2010; 17(30):3514-32. PubMed ID: 20738248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs.
    Perry M; Stansfeld PJ; Leaney J; Wood C; de Groot MJ; Leishman D; Sutcliffe MJ; Mitcheson JS
    Mol Pharmacol; 2006 Feb; 69(2):509-19. PubMed ID: 16291873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
    Zachariae U; Giordanetto F; Leach AG
    J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding of molecular substructures that contribute to hERG K+ channel blockade: synthesis and biological evaluation of E-4031 analogues.
    Vilums M; Overman J; Klaasse E; Scheel O; Brussee J; IJzerman AP
    ChemMedChem; 2012 Jan; 7(1):107-13. PubMed ID: 21919210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular determinants of dofetilide block of HERG K+ channels.
    Ficker E; Jarolimek W; Kiehn J; Baumann A; Brown AM
    Circ Res; 1998 Feb; 82(3):386-95. PubMed ID: 9486667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
    Thomas D; Wendt-Nordahl G; Röckl K; Ficker E; Brown AM; Kiehn J
    J Pharmacol Exp Ther; 2001 May; 297(2):753-61. PubMed ID: 11303067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
    Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
    Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.